Reduced anoctamin 7 (ANO7) expression is a strong and independent predictor of poor prognosis in prostate cancer.


Journal

Cancer biology & medicine
ISSN: 2095-3941
Titre abrégé: Cancer Biol Med
Pays: China
ID NLM: 101588850

Informations de publication

Date de publication:
15 02 2021
Historique:
received: 25 09 2019
accepted: 07 02 2020
entrez: 25 2 2021
pubmed: 26 2 2021
medline: 15 12 2021
Statut: ppublish

Résumé

Anoctamin 7 (ANO7) is a calcium ANO7 expression was assessed by immunohistochemistry in 17,747 clinical PCa specimens. ANO7 was strongly expressed in normal prostate glandular cells but often less abundant in cancer cells. ANO7 staining was interpretable in 13,594 cancer tissues and considered strong in 34.4%, moderate in 48.7%, weak in 9.3%, and negative in 7.6%. Reduced staining was tightly linked to adverse tumor features [high classical and quantitative Gleason grade, lymph node metastasis, advanced tumor stage, high Ki67 labeling index, positive surgical margin, and early biochemical recurrence ( These data identify reduced ANO7 protein expression as a strong and independent predictor of poor prognosis in PCa. ANO7 measurement, either alone or in combination, might provide clinically useful prognostic information in PCa.

Identifiants

pubmed: 33628598
doi: 10.20892/j.issn.2095-3941.2019.0324
pii: j.issn.2095-3941.2019.0324
pmc: PMC7877177
doi:

Substances chimiques

ANO7 protein, human 0
Anoctamins 0
Biomarkers, Tumor 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

245-255

Informations de copyright

Copyright: © 2021, Cancer Biology & Medicine.

Déclaration de conflit d'intérêts

Conflict of interest statement No potential conflicts of interest are disclosed.

Références

Database (Oxford). 2017 Jan 1;2017:
pubmed: 28605766
Cancer Manag Res. 2018 Nov 09;10:5491-5504
pubmed: 30519097
Am J Pathol. 2012 Aug;181(2):401-12
pubmed: 22705054
Eur Urol. 2016 Apr;69(4):592-598
pubmed: 26542947
Oncotarget. 2019 Sep 10;10(52):5439-5453
pubmed: 31534629
Cancer Immunol Immunother. 2013 Oct;62(10):1609-18
pubmed: 23955683
Int J Cancer. 2011 Nov 15;129(10):2400-7
pubmed: 21207418
Oncotarget. 2016 Dec 27;7(52):86339-86349
pubmed: 27861151
Int J Cancer. 2014 Sep 15;135(6):1369-80
pubmed: 24523142
Cancer Res. 2008 Aug 1;68(15):6306-12
pubmed: 18676855
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Exp Mol Pathol. 2018 Aug;105(1):50-56
pubmed: 29803408
Prostate. 2011 Feb 15;71(3):281-8
pubmed: 20809553
Genes Chromosomes Cancer. 2018 Oct;57(10):504-512
pubmed: 29923647
Cancer Cell. 2013 Feb 11;23(2):159-70
pubmed: 23410972
BMC Cancer. 2015 Jul 23;15:538
pubmed: 26202067
Cancer Res. 2007 Feb 15;67(4):1594-601
pubmed: 17308099
Int J Oncol. 2012 Jan;40(1):261-8
pubmed: 21956230
Nat Med. 1998 Jul;4(7):844-7
pubmed: 9662379
Philos Trans R Soc Lond B Biol Sci. 2014 Feb 03;369(1638):20130096
pubmed: 24493744
Cancer Res. 2010 Feb 1;70(3):896-905
pubmed: 20103641
Int J Cancer. 2018 Nov 15;143(10):2479-2487
pubmed: 30157291
Proc Natl Acad Sci U S A. 2013 Mar 12;110(11):E1026-34
pubmed: 23431153
Biomark Med. 2015;9(4):391-401
pubmed: 25808443
Appl Immunohistochem Mol Morphol. 2009 Oct;17(5):413-8
pubmed: 19417627
J Pathol. 2013 Sep;231(1):130-41
pubmed: 23794398
Oncogene. 2006 Mar 16;25(12):1821-31
pubmed: 16261155
Cancer Discov. 2012 May;2(5):401-4
pubmed: 22588877
Annu Rev Cell Dev Biol. 2015;31:231-47
pubmed: 26566112
Oncotarget. 2015 Sep 29;6(29):27966-79
pubmed: 26293672
Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):3059-64
pubmed: 14981236
Cancer Res. 2013 May 1;73(9):2795-805
pubmed: 23492366
Cancers (Basel). 2019 Mar 19;11(3):
pubmed: 30893776
Diagn Pathol. 2019 May 1;14(1):33
pubmed: 31043167
Oncotarget. 2017 Nov 11;8(65):108923-108935
pubmed: 29312579
Clin Cancer Res. 2011 Sep 15;17(18):5878-88
pubmed: 21791629
Oncotarget. 2017 Jan 3;8(1):379-392
pubmed: 27880722
Mod Pathol. 2013 Jul;26(7):975-83
pubmed: 23370768
Oncotarget. 2016 Nov 29;7(48):78619-78630
pubmed: 27732935
Oncotarget. 2017 Jun 27;8(49):84996-85013
pubmed: 29156699
Int J Oncol. 2018 Oct;53(4):1435-1441
pubmed: 30066845

Auteurs

Andreas Marx (A)

Institute of Pathology, Klinikum Fürth, Fürth 90766, Germany.

Lena Koopmann (L)

Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg 20246, Germany.

Doris Höflmayer (D)

Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg 20246, Germany.

Franziska Büscheck (F)

Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg 20246, Germany.

Claudia Hube-Magg (C)

Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg 20246, Germany.

Stefan Steurer (S)

Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg 20246, Germany.

Till Eichenauer (T)

Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg 20246, Germany.

Till S Clauditz (TS)

Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg 20246, Germany.

Waldemar Wilczak (W)

Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg 20246, Germany.

Ronald Simon (R)

Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg 20246, Germany.

Guido Sauter (G)

Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg 20246, Germany.

Jakob R Izbicki (JR)

General, Visceral and Thoracic Surgery Department and Clinic, University Medical Center Hamburg-Eppendorf, Hamburg 20246, Germany.

Hartwig Huland (H)

Martini-Clinic, Prostate Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg 20246, Germany.

Hans Heinzer (H)

Martini-Clinic, Prostate Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg 20246, Germany.

Markus Graefen (M)

Martini-Clinic, Prostate Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg 20246, Germany.

Alexander Haese (A)

Martini-Clinic, Prostate Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg 20246, Germany.

Thorsten Schlomm (T)

Department of Urology, Charité - Universitätsmedizin Berlin, Berlin 10117, Germany.

Christian Bernreuther (C)

Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg 20246, Germany.

Patrick Lebok (P)

Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg 20246, Germany.

Sarah Bonk (S)

Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg 20246, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH